New trial aims to spare colon cancer patients from surgery
NCT ID NCT05961709
Summary
This study is testing if an immunotherapy drug called cemiplimab can effectively control a specific type of colon cancer that has a DNA repair defect (dMMR/MSI-H). The goal is to see if the drug can shrink or eliminate the tumor enough that some patients might avoid having surgery to remove part of their colon. The trial will enroll about 50 adults with localized colon cancer to receive the drug and be closely monitored.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Banner - MD Anderson Cancer
RECRUITINGGilbert, Arizona, 85234, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Baptist - MD Anderson Cancer Center
RECRUITINGJacksonville, Florida, 32207, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cooper University Medical Center
RECRUITINGCamden, New Jersey, 08103, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ochsner
RECRUITINGNew Orleans, Louisiana, 70121, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.